The wet form of age-related macular degeneration (AMD) is currently treated with eye drugs that are blockbuster sellers. Opthea Limited is developing a wet AMD drug that goes after different targets and the biotech struck a pair of financing deals that provide it with the cash for pivotal tests that could show how well its approach works.
AMD in particular impacts as many as 11 million Americans. About 15% of those affected have neovascular or wet AMD. It’s a devastating disease that can lead to irreversible vision loss.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
AbbVie will take the lead on commercializing Regenxbio’s gene therapy in wet AMD and diabetic retinopathy. It’s AbbVie’s second major gene therapy deal this year, coming months after it committed $90 million to preclinical-stage Capsida Biotherapeutics.
The reason Tyrogenex is using a compound for both wet AMD and cancer because both diseases, the company says, stem from the uncontrolled growth of blood cells.
One of the most commonly prescribed drugs for wet age-related macular degeneration is Avastin – a cancer drug. So it’s not that surprising that a new approach for wet AMD is radiation therapy – with aims to halt the growth of the unruly blood vessels that cause the disease. Arizona startup Salutaris Medical Devices is developing a device […]